Blood-Based Biomarkers for Post-Stroke Cognitive Impairment
Abstract
Stroke remains the second leading cause of death and the third leading cause of death and disability. With the growing incidence of strokes, the incidence of post-stroke cognitive impairment (PSCI) among patients is on a steady rise. These patients commonly present with impairments in memory, attention, executive function, comprehension, and judgment, substantially affecting their everyday lives. Magnetic resonance image (MRI) and cognitive assessment scales are widely employed as diagnostic tools for PSCI. They also have notable limitations. Furthermore, cerebrospinal fluid collection is relatively complex. Growing evidence suggests that blood-based biomarkers are closely involved in the onset and progression of PSCI, as bioassay techniques and equipment have become increasingly popular and optimized. Therefore, blood-based biomarkers play an essential role in the pathogenesis and progression of PSCI. This review concentrates on the research progress of blood-based biomarkers in PSCI to explore their significance for disease identification, with the aim of offering novel insights into the clinical diagnosis and therapy of PSCI.
Read the paper
Related studies
- Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
- Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
- Antioxidants, inflammation and cardiovascular disease
- Application of Metabolomics in Alzheimer’s Disease
- Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review
- Nutritional essentiality of sulfur in health and disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.